ZA200405507B - Nitric oxide donors for treatment of disease and injury - Google Patents
Nitric oxide donors for treatment of disease and injury Download PDFInfo
- Publication number
- ZA200405507B ZA200405507B ZA2004/05507A ZA200405507A ZA200405507B ZA 200405507 B ZA200405507 B ZA 200405507B ZA 2004/05507 A ZA2004/05507 A ZA 2004/05507A ZA 200405507 A ZA200405507 A ZA 200405507A ZA 200405507 B ZA200405507 B ZA 200405507B
- Authority
- ZA
- South Africa
- Prior art keywords
- cells
- rats
- sildenafil
- brain
- treatment
- Prior art date
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title claims description 149
- 238000011282 treatment Methods 0.000 title description 86
- 239000002840 nitric oxide donor Substances 0.000 title description 29
- 230000006378 damage Effects 0.000 title description 24
- 208000027418 Wounds and injury Diseases 0.000 title description 21
- 208000014674 injury Diseases 0.000 title description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 15
- 201000010099 disease Diseases 0.000 title description 14
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 192
- 229960003310 sildenafil Drugs 0.000 claims description 95
- 230000001965 increasing effect Effects 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 53
- 150000001875 compounds Chemical class 0.000 claims description 41
- 230000004766 neurogenesis Effects 0.000 claims description 40
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 21
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 20
- 238000002659 cell therapy Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 210000002569 neuron Anatomy 0.000 claims description 13
- 230000001737 promoting effect Effects 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 230000003190 augmentative effect Effects 0.000 claims description 4
- 230000007658 neurological function Effects 0.000 claims description 4
- 230000003416 augmentation Effects 0.000 claims description 3
- 230000003920 cognitive function Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 241000700159 Rattus Species 0.000 description 130
- 210000004027 cell Anatomy 0.000 description 120
- 210000004556 brain Anatomy 0.000 description 86
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 68
- 230000033115 angiogenesis Effects 0.000 description 65
- 230000000302 ischemic effect Effects 0.000 description 63
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 54
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 54
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 54
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 54
- 208000006011 Stroke Diseases 0.000 description 53
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 52
- 229950004398 broxuridine Drugs 0.000 description 52
- YNRCBOXEDICOIX-CLFYSBASSA-N (Z)-[bis(2-aminoethyl)amino]-hydroxyimino-oxidoazanium Chemical compound NCCN(CC[NH3+])[N+](\[O-])=N\[O-] YNRCBOXEDICOIX-CLFYSBASSA-N 0.000 description 51
- 230000015572 biosynthetic process Effects 0.000 description 45
- 230000000694 effects Effects 0.000 description 44
- 241001465754 Metazoa Species 0.000 description 41
- 210000002889 endothelial cell Anatomy 0.000 description 40
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 36
- 210000000130 stem cell Anatomy 0.000 description 34
- 230000003447 ipsilateral effect Effects 0.000 description 29
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 28
- 230000004663 cell proliferation Effects 0.000 description 26
- 210000001947 dentate gyrus Anatomy 0.000 description 26
- 238000012360 testing method Methods 0.000 description 24
- 208000028867 ischemia Diseases 0.000 description 23
- 230000006870 function Effects 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 22
- 206010061216 Infarction Diseases 0.000 description 21
- 230000007574 infarction Effects 0.000 description 21
- 230000006872 improvement Effects 0.000 description 20
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 19
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 19
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 19
- 210000003657 middle cerebral artery Anatomy 0.000 description 18
- 238000002560 therapeutic procedure Methods 0.000 description 18
- 206010019280 Heart failures Diseases 0.000 description 16
- 230000008901 benefit Effects 0.000 description 16
- 230000037396 body weight Effects 0.000 description 16
- 210000000988 bone and bone Anatomy 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 230000002490 cerebral effect Effects 0.000 description 14
- 210000000956 olfactory bulb Anatomy 0.000 description 14
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 13
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 13
- 210000001185 bone marrow Anatomy 0.000 description 13
- 210000002216 heart Anatomy 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 238000011084 recovery Methods 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- LZMHWZHOZLVYDL-UHFFFAOYSA-N 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one Chemical compound C1=CC=C2N3C(=O)ON=C3C=NC2=C1 LZMHWZHOZLVYDL-UHFFFAOYSA-N 0.000 description 12
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 12
- 230000003727 cerebral blood flow Effects 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 230000002792 vascular Effects 0.000 description 12
- 239000000853 adhesive Substances 0.000 description 11
- 230000001070 adhesive effect Effects 0.000 description 11
- 210000001577 neostriatum Anatomy 0.000 description 11
- 230000000926 neurological effect Effects 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- 101000578287 Homo sapiens Non-POU domain-containing octamer-binding protein Proteins 0.000 description 9
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 9
- 102100028102 Non-POU domain-containing octamer-binding protein Human genes 0.000 description 9
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 9
- 206010008118 cerebral infarction Diseases 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000001537 neural effect Effects 0.000 description 9
- ZIIQCSMRQKCOCT-YFKPBYRVSA-N S-nitroso-N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-YFKPBYRVSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 210000005013 brain tissue Anatomy 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 101100296726 Caenorhabditis elegans pde-5 gene Proteins 0.000 description 7
- -1 IBMX Chemical compound 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004413 cardiac myocyte Anatomy 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 238000002648 combination therapy Methods 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000003073 embolic effect Effects 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 208000012902 Nervous system disease Diseases 0.000 description 6
- 241000700157 Rattus norvegicus Species 0.000 description 6
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 210000002064 heart cell Anatomy 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000008399 tap water Substances 0.000 description 5
- 235000020679 tap water Nutrition 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 4
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 4
- 101000808006 Rattus norvegicus Vascular endothelial growth factor A Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 108091008605 VEGF receptors Proteins 0.000 description 4
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 230000001054 cortical effect Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 230000007514 neuronal growth Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 210000001638 cerebellum Anatomy 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229960001484 edetic acid Drugs 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000003194 forelimb Anatomy 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000007154 intracellular accumulation Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000003140 lateral ventricle Anatomy 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 238000011422 pharmacological therapy Methods 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- REZGGXNDEMKIQB-UHFFFAOYSA-N zaprinast Chemical compound CCCOC1=CC=CC=C1C1=NC(=O)C2=NNNC2=N1 REZGGXNDEMKIQB-UHFFFAOYSA-N 0.000 description 3
- 229950005371 zaprinast Drugs 0.000 description 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- FLYJEBSUJDZJDE-UHFFFAOYSA-N 3-phenyl-1h-pyridin-2-one Chemical class O=C1NC=CC=C1C1=CC=CC=C1 FLYJEBSUJDZJDE-UHFFFAOYSA-N 0.000 description 2
- 108010009906 Angiopoietins Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 2
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- 229940094419 Guanylate cyclase inhibitor Drugs 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 101150098694 PDE5A gene Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 2
- 239000004068 calcium phosphate ceramic Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000001627 cerebral artery Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000003126 guanylate cyclase inhibitor Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000007654 ischemic lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000002629 repopulating effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229960002639 sildenafil citrate Drugs 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 229940094720 viagra Drugs 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- IAPZXUKYTCQQFE-QZKDJMESSA-N (2r,3r,3as,5s)-2-(6-aminopurin-9-yl)-5-[carboxy(hydroxy)methyl]-3-hydroxy-3,3a-dihydro-2h-furo[3,2-b]furan-5-carboxylic acid Chemical class NC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@@H]2O[C@](C(O)=O)(C(O)C(O)=O)C=C2O1 IAPZXUKYTCQQFE-QZKDJMESSA-N 0.000 description 1
- YSUBQYRZZFVMTL-YNDGFOBUSA-N (2s,5r,6r)-6-[[(2r)-2-[[3-[(e)-furan-2-ylmethylideneamino]-2-oxoimidazolidine-1-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)N(C1=O)CCN1\N=C\C1=CC=CO1 YSUBQYRZZFVMTL-YNDGFOBUSA-N 0.000 description 1
- STVYBUMQUAJDER-PEZBUJJGSA-N (Z)-[3-aminopropyl-[4-(3-aminopropylamino)butyl]amino]-hydroxyimino-oxidoazanium Chemical compound NCCC[NH2+]CCCCN([N+](\[O-])=N\[O-])CCCN STVYBUMQUAJDER-PEZBUJJGSA-N 0.000 description 1
- DLNIKTWGBUNSSV-LUAWRHEFSA-N (Z)-[bis(3-aminopropyl)amino]-hydroxyimino-oxidoazanium Chemical compound NCCCN([N+](\[O-])=N\[O-])CCC[NH3+] DLNIKTWGBUNSSV-LUAWRHEFSA-N 0.000 description 1
- FOSISNXVGQBIAP-ALCCZGGFSA-N (Z)-diethylamino-hydroxyimino-oxidoazanium Chemical compound CCN(CC)[N+](\[O-])=N\O FOSISNXVGQBIAP-ALCCZGGFSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- BYKFPARGCLDSFK-UHFFFAOYSA-N 1-[4-(1,3-benzodioxol-5-ylmethylamino)-6-nitroquinazolin-2-yl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=NC(NCC=2C=C3OCOC3=CC=2)=C(C=C(C=C2)[N+]([O-])=O)C2=N1 BYKFPARGCLDSFK-UHFFFAOYSA-N 0.000 description 1
- GODZWYONGRENHA-UHFFFAOYSA-N 1-cyclopentyl-3-methyl-6-pyridin-4-yl-5H-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=2N=C(C=3C=CN=CC=3)NC(=O)C=2C(C)=NN1C1CCCC1 GODZWYONGRENHA-UHFFFAOYSA-N 0.000 description 1
- ZAUYNCUCMJDAHW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;hydrogen peroxide;molecular iodine Chemical compound OO.II.C=CN1CCCC1=O ZAUYNCUCMJDAHW-UHFFFAOYSA-N 0.000 description 1
- PBRFQQAUEOPPGQ-UHFFFAOYSA-N 1-ethyl-3-methyl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C1=CC=C2NC(=O)C3=C(C)N=C(CC)N3C2=C1 PBRFQQAUEOPPGQ-UHFFFAOYSA-N 0.000 description 1
- BRBNVIXMODBSND-UHFFFAOYSA-N 1-methyl-5-[5-(2-morpholin-4-ylacetyl)-2-propoxyphenyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1=C(C=2NC(=O)C=3N(C)N=C(CCC)C=3N=2)C(OCCC)=CC=C1C(=O)CN1CCOCC1 BRBNVIXMODBSND-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZIIQCSMRQKCOCT-UHFFFAOYSA-N 2-acetamido-3-methyl-3-nitrososulfanylbutanoic acid Chemical compound CC(=O)NC(C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-UHFFFAOYSA-N 0.000 description 1
- ZEDCOUIRGFQKTH-UHFFFAOYSA-N 3-acetyl-1-[(2-chlorophenyl)methyl]-2-propylindole-6-carboxylic acid Chemical compound CCCC1=C(C(C)=O)C2=CC=C(C(O)=O)C=C2N1CC1=CC=CC=C1Cl ZEDCOUIRGFQKTH-UHFFFAOYSA-N 0.000 description 1
- OULXFNCZTZKFKS-UHFFFAOYSA-N 4-ethoxy-2-phenylcyclohepta[d]imidazole Chemical compound N1=C2C(OCC)=CC=CC=C2N=C1C1=CC=CC=C1 OULXFNCZTZKFKS-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- GFVZTCIYHIUUJO-UHFFFAOYSA-N 5-[2-ethoxy-5-(1-methylimidazol-2-yl)phenyl]-1-methyl-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1C1=NC=CN1C GFVZTCIYHIUUJO-UHFFFAOYSA-N 0.000 description 1
- QPBXXHOQSFVUKL-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-2-ylmethylamino)-1h-pyridazin-6-one Chemical compound C1=CC(Cl)=CC=C1CCCOC1=NNC(=O)C(Br)=C1NCC1=CC=CC=N1 QPBXXHOQSFVUKL-UHFFFAOYSA-N 0.000 description 1
- YJMYSLFFZJUXOA-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C1=CC(Cl)=CC=C1CCCOC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 YJMYSLFFZJUXOA-UHFFFAOYSA-N 0.000 description 1
- LDORHCBMWSQLIU-UHFFFAOYSA-N 6-phenyl-1h-pyrimidin-2-one Chemical class N1C(=O)N=CC=C1C1=CC=CC=C1 LDORHCBMWSQLIU-UHFFFAOYSA-N 0.000 description 1
- YUFCOOWNNHGGOD-UMMCILCDSA-N 8-bromo-3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1Br YUFCOOWNNHGGOD-UMMCILCDSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- LHCXHDQPKHYQPB-UHFFFAOYSA-O CCCN(N([O-])N=O)CCC[NH3+] Chemical compound CCCN(N([O-])N=O)CCC[NH3+] LHCXHDQPKHYQPB-UHFFFAOYSA-O 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101100379080 Emericella variicolor andB gene Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101100268553 Homo sapiens APP gene Proteins 0.000 description 1
- 101100231743 Homo sapiens HPRT1 gene Proteins 0.000 description 1
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 206010061223 Ligament injury Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 description 1
- 208000029027 Musculoskeletal and connective tissue disease Diseases 0.000 description 1
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- QODRTFHTYGHQMT-NTMALXAHSA-N PAPA NONOate Chemical compound CCCN([N+](\[O-])=N\[O-])CCC[NH3+] QODRTFHTYGHQMT-NTMALXAHSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 238000010161 Student-Newman-Keuls test Methods 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000021945 Tendon injury Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- HZRNGLPDDYCHGF-UHFFFAOYSA-N [4-(benzylamino)-6-chloroquinazolin-2-yl]-imidazol-1-ylmethanone Chemical compound C12=CC(Cl)=CC=C2N=C(C(=O)N2C=NC=C2)N=C1NCC1=CC=CC=C1 HZRNGLPDDYCHGF-UHFFFAOYSA-N 0.000 description 1
- JCXWFCXMYYIOKX-UHFFFAOYSA-N [Na].OCC(O)C(O)[N+]([O-])=O Chemical compound [Na].OCC(O)C(O)[N+]([O-])=O JCXWFCXMYYIOKX-UHFFFAOYSA-N 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 125000000477 aza group Chemical group 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 210000001841 basilar artery Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000003222 cGMP degradation Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000004662 cellular morphological change Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- CRFFZGAVKNNBKJ-UHFFFAOYSA-N chembl45367 Chemical compound CCCOC1=CC=C(NS(C)(=O)=O)C=C1C(NC1=O)=NC2=C1C(C)=NN2C CRFFZGAVKNNBKJ-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000004141 dimensional analysis Methods 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 210000004565 granule cell Anatomy 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 210000001564 haversian system Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- UVNXNSUKKOLFBM-UHFFFAOYSA-N imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=CSC2=NC=CN21 UVNXNSUKKOLFBM-UHFFFAOYSA-N 0.000 description 1
- HOFSPGAYXKNFAM-UHFFFAOYSA-N imidazo[4,5-f]quinoxalin-2-one Chemical class C1=CN=C2C3=NC(=O)N=C3C=CC2=N1 HOFSPGAYXKNFAM-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000013150 knee replacement Methods 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000001930 leg bone Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 229960003574 milrinone Drugs 0.000 description 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- DMDOTRUOIVBPSF-UHFFFAOYSA-N naphthalene;hydrochloride Chemical compound Cl.C1=CC=CC2=CC=CC=C21 DMDOTRUOIVBPSF-UHFFFAOYSA-N 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000002182 neurohumoral effect Effects 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 238000011859 neuroprotective therapy Methods 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000012402 patch clamp technique Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000001292 preischemic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical class N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 238000010825 rotarod performance test Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- JOSMPBVYYKRYLG-OLZOCXBDSA-N sch-51866 Chemical compound N1([C@H]2CCC[C@H]2N=C1N(C(C=1N2)=O)C)C=1N=C2CC1=CC=C(C(F)(F)F)C=C1 JOSMPBVYYKRYLG-OLZOCXBDSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000004873 systolic arterial blood pressure Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 1
- 229960002312 tolazoline Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34547802P | 2002-01-04 | 2002-01-04 | |
| PCT/US2003/000323 WO2003056899A2 (en) | 2002-01-04 | 2003-01-06 | Nitric oxide donors for treatment of disease and injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200405507B true ZA200405507B (en) | 2005-05-25 |
Family
ID=23355218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2004/05507A ZA200405507B (en) | 2002-01-04 | 2004-07-12 | Nitric oxide donors for treatment of disease and injury |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20050143388A1 (https=) |
| EP (1) | EP1469852A4 (https=) |
| JP (2) | JP4545440B2 (https=) |
| CN (1) | CN1638775A (https=) |
| AU (1) | AU2003210447B2 (https=) |
| CA (1) | CA2471147C (https=) |
| IL (1) | IL162850A0 (https=) |
| WO (1) | WO2003056899A2 (https=) |
| ZA (1) | ZA200405507B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007010337A2 (de) * | 2005-07-15 | 2007-01-25 | Proxomed Medizintechnik Gmbh | Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von adipositas, sowie abgabesysteme für dieselben |
| CA2629463A1 (en) * | 2005-11-14 | 2008-02-21 | Scott A. Small | Imaging correlates of neurogenesis with mri |
| US8841300B2 (en) | 2006-10-02 | 2014-09-23 | Jerry M. Held | Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor |
| CN101754756A (zh) * | 2007-05-18 | 2010-06-23 | 维瓦斯公司 | 包含磷酸二酯酶-5抑制剂的新组合和它们的用途 |
| WO2009046377A2 (en) * | 2007-10-04 | 2009-04-09 | Medistem Laboratories, Inc. | Compositions and methods of stem cell therapy for autism |
| US20100316622A1 (en) * | 2007-11-02 | 2010-12-16 | University Of Miami | Diagnosis and treatment of cardiac disorders |
| NZ631258A (en) | 2012-04-25 | 2016-11-25 | Takeda Pharmaceuticals Co | Nitrogenated heterocyclic compound |
| WO2014010732A1 (ja) | 2012-07-13 | 2014-01-16 | 武田薬品工業株式会社 | 複素環化合物 |
| ES2635016T3 (es) * | 2013-03-01 | 2017-10-02 | Fundación Para La Investigación Médica Aplicada | Nuevos compuestos como inhibidores duales de fosfodiesterasas e histonas deacetilasas |
| EP2975031A4 (en) | 2013-03-14 | 2017-04-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP6427491B2 (ja) | 2013-07-03 | 2018-11-21 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3018123B1 (en) | 2013-07-03 | 2023-05-10 | Takeda Pharmaceutical Company Limited | Amide compound |
| US10297661B2 (en) * | 2017-06-30 | 2019-05-21 | Taiwan Semiconductor Manufacturing Co., Ltd. | High voltage resistor device |
| JP7770572B2 (ja) * | 2021-12-14 | 2025-11-14 | チェンアオ ジンインファ ファーマシューティカル | 虚血性脳損傷を予防または治療するための医薬の調製におけるアイルデナフィルまたはその塩の使用 |
| TWI879058B (zh) * | 2023-08-31 | 2025-04-01 | 未來新藥股份有限公司 | Pde5抑制劑組合於促進神經突生長之新穎用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2224195A (en) * | 1994-04-15 | 1995-11-10 | Masaomi Iyo | Medicinal composition for treating tardive dyskinesia and utilization thereof |
| US5827740A (en) * | 1996-07-30 | 1998-10-27 | Osiris Therapeutics, Inc. | Adipogenic differentiation of human mesenchymal stem cells |
| US6043224A (en) * | 1996-09-05 | 2000-03-28 | The Massachusetts Institute Of Technology | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| US6043223A (en) * | 1997-11-12 | 2000-03-28 | The Regents Of The University Of California | Enhanced opening of abnormal brain tissue capillaries |
| DE19834507A1 (de) * | 1998-07-31 | 2000-02-03 | Hexal Ag | Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil |
| ES2531592T3 (es) * | 1999-05-14 | 2015-03-17 | Henry Ford Health System | Trasplante de médula ósea para el tratamiento de la apoplejía |
| EP1233670B1 (en) * | 1999-06-14 | 2008-09-17 | Henry Ford Health System | Nitric oxide donors for inducing neurogenesis |
| US6075028A (en) * | 1999-09-23 | 2000-06-13 | Graham; Richard | Method of treating Tourette's syndrome and related CNS disorders |
| IL139073A0 (en) * | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
| US6271228B1 (en) | 2000-04-28 | 2001-08-07 | Pfizer Inc. | Blood pressure stabilization during hemodialysis |
| EP2316531A1 (en) * | 2000-08-10 | 2011-05-04 | Cold Spring Harbor Laboratory | Augmented cognitive training |
-
2003
- 2003-01-06 EP EP03729347A patent/EP1469852A4/en not_active Withdrawn
- 2003-01-06 CN CNA038048817A patent/CN1638775A/zh active Pending
- 2003-01-06 IL IL16285003A patent/IL162850A0/xx unknown
- 2003-01-06 AU AU2003210447A patent/AU2003210447B2/en not_active Ceased
- 2003-01-06 JP JP2003557275A patent/JP4545440B2/ja not_active Expired - Fee Related
- 2003-01-06 CA CA2471147A patent/CA2471147C/en not_active Expired - Fee Related
- 2003-01-06 WO PCT/US2003/000323 patent/WO2003056899A2/en not_active Ceased
- 2003-01-06 US US10/500,694 patent/US20050143388A1/en not_active Abandoned
-
2004
- 2004-07-12 ZA ZA2004/05507A patent/ZA200405507B/en unknown
-
2009
- 2009-08-04 JP JP2009181759A patent/JP2009256374A/ja active Pending
-
2010
- 2010-09-24 US US12/889,873 patent/US20120009152A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003056899A2 (en) | 2003-07-17 |
| US20050143388A1 (en) | 2005-06-30 |
| JP2009256374A (ja) | 2009-11-05 |
| US20120009152A1 (en) | 2012-01-12 |
| CA2471147A1 (en) | 2003-07-17 |
| EP1469852A2 (en) | 2004-10-27 |
| EP1469852A4 (en) | 2009-12-02 |
| CN1638775A (zh) | 2005-07-13 |
| JP4545440B2 (ja) | 2010-09-15 |
| WO2003056899A3 (en) | 2003-11-27 |
| AU2003210447A1 (en) | 2003-07-24 |
| WO2003056899A9 (en) | 2004-04-15 |
| IL162850A0 (en) | 2005-11-20 |
| AU2003210447B2 (en) | 2008-02-07 |
| CA2471147C (en) | 2010-08-10 |
| JP2005514406A (ja) | 2005-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120009152A1 (en) | Nitric oxide donors for treatment of disease and injury | |
| US9394520B2 (en) | Expansion of hematopoietic stem cells | |
| US7658951B2 (en) | Method of improving cardiac function of a diseased heart | |
| US7514261B2 (en) | Platelet-derived growth factor protection of cardiac myocardium | |
| US8309095B2 (en) | Parathyroid hormone receptor activation and stem and progenitor cell expansion | |
| US20050158397A1 (en) | Materials from bone marrow stromal cells for use in forming blood vessels and producing angiogenic and trophic factors | |
| US20020155173A1 (en) | Nitric oxide donors for inducing neurogenesis | |
| KR20050000400A (ko) | 줄기 및 전구 세포 분화의 조절, 측정 및 이들의 용도 | |
| JP6560332B2 (ja) | 単一サイクルでコンディショニングおよび化学選択を組み合わせる方法 | |
| US7776334B2 (en) | Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion | |
| JP2004529916A (ja) | パーキンソン病の治療において神経栄養活性化合物と組み合わせたアデノシンａ２ａレセプターアンタゴニスト | |
| KR102709789B1 (ko) | 봉크렉산에 의한 조골세포 활성화를 통한 골질환 치료용 조성물 | |
| JP5500773B2 (ja) | 副甲状腺ホルモン受容体の活性化並びに幹細胞及び前駆細胞の増殖 | |
| US20070244037A1 (en) | Human Chemokine HCC-1 Polypeptides To Improve Stem Cell Transplantation | |
| AU2002339944A1 (en) | Cardiac transplantation of stem cells for the treatment of heart failure |